| Literature DB >> 19092153 |
Charline Ladroue1, Romain Carcenac, Michel Leporrier, Sophie Gad, Claire Le Hello, Françoise Galateau-Salle, Jean Feunteun, Jacques Pouysségur, Stéphane Richard, Betty Gardie.
Abstract
Prolyl hydroxylase domain (PHD) proteins play a major role in regulating the hypoxia-inducible factor (HIF) that induces expression of genes involved in angiogenesis, erythropoiesis, and cell metabolism, proliferation, and survival. Germ-line mutations in the prolyl hydroxylase domain 2 gene (PHD2) have been reported in patients with familial erythrocytosis but not in association with tumors. We describe a patient with erythrocytosis and recurrent paraganglioma who carries a newly discovered PHD2 mutation. This mutation affects PHD2 function and stabilizes HIF-alpha proteins. In addition, we demonstrate loss of heterozygosity of PHD2 in the tumor, suggesting that PHD2 could be a tumor-suppressor gene. 2008 Massachusetts Medical SocietyEntities:
Mesh:
Substances:
Year: 2008 PMID: 19092153 DOI: 10.1056/NEJMoa0806277
Source DB: PubMed Journal: N Engl J Med ISSN: 0028-4793 Impact factor: 91.245